KALA BIO, Inc. (NASDAQ: KALA) announced the implementation of a 1-for-50 reverse stock split of its common stock, effective at 4:05 p.m. on May 8, 2026. Split-adjusted trading is set to begin on the Nasdaq Capital Market at the open on May 11, 2026. The reverse split will reduce the company's outstanding common shares from approximately 929.5 million to 18.6 million, with cash payments issued in lieu of fractional shares and proportional adjustments made to outstanding equity awards, warrants and other convertible securities. This corporate action is typically undertaken to increase the per-share trading price to meet Nasdaq's minimum bid price requirement for continued listing.
KALA BIO is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The company's dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business designed to deploy secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments.
Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. The company's focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector.
The reverse stock split is a significant event for shareholders and potential investors, as it consolidates the number of shares outstanding and typically increases the stock price proportionally. For KALA BIO, this move may help the company maintain its listing on the Nasdaq Capital Market, ensuring continued access to public capital markets. For the broader biotechnology industry, KALA's strategy of combining AI infrastructure with biologics development represents a novel approach that could influence how other companies leverage artificial intelligence in drug discovery and development.
KALA BIO's focus on on-premises AI deployment addresses growing concerns about data security and control in the life sciences sector. By offering a platform that keeps proprietary biological data within client environments, the company is positioning itself as a trusted partner for biotech and pharmaceutical firms. The reverse stock split, while a financial maneuver, supports the company's long-term strategic goals by potentially stabilizing its stock price and attracting a broader investor base.
